Final dosimetry results of IDEC-Y2B8 phase I II 90yttrium radioimmunothenapy trial in non-Hodgkin's lymphoma (NHL).

被引：0
|
作者：
Wiseman, GA
White, CA
Witzig, TA
Stabin, MG
Spies, S
Silverman, DH
Raubitschek, A
Gordon, L
Emmanouilides, C
Janakiraman, N
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Idec Pharmaceut Corp, San Diego, CA USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[6] Henry Ford Hosp, Detroit, MI 48202 USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 1999年 / 40卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
260
引用
收藏
页码：64P / 64P
页数：1
相关论文
共 50 条
  • [31] Update on interim results in Genta's anticode phase I/II non-Hodgkin's lymphoma trial presented
    不详
    DRUG NEWS & PERSPECTIVES, 1996, 9 (06) : 364 - 365
  • [32] Phase I/II radioimmunotherapy trial with 90Y-labeled epratuzumab (LymphoCide™ anti-CD22 monoclonal antibody) in relapsed/refractory non-Hodgkin's lymphoma (NHL).
    Hajjar, G
    Burton, JD
    Sharkey, RM
    Schuster, SL
    Czuczman, M
    Lamonica, D
    Chatal, JF
    Alavi, A
    Stadtmauer, E
    Leonard, JP
    Coleman, M
    Goldenberg, DM
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 156P - 156P
  • [33] IDEC-C2B8 - FINAL REPORT ON A PHASE-II TRIAL IN RELAPSED NON-HODGKINS-LYMPHOMA
    MALONEY, DG
    BODKIN, D
    GRILLOLOPEZ, AJ
    WHITE, C
    FOON, K
    SCHILDER, R
    NEIDHART, J
    JANAKIRAMAN, N
    WALDICHUK, C
    VARNS, C
    ROYSTON, I
    LEVY, R
    BLOOD, 1994, 84 (10) : A169 - A169
  • [34] Phase 2 multicenter trial of gallium nitrate in patients with advanced non-Hodgkin's lymphoma (NHL).
    Pro, B
    Bociek, RG
    Chitambar, CR
    Gregory, SA
    Leonard, JP
    Smith, S
    Novick, S
    BLOOD, 2004, 104 (11) : 682A - 682A
  • [35] Results of a phase I/II trial of pixantrone in combination with fludarabine, dexamethasone, and rituximab in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).
    Fayad, Luis
    Liebmann, James
    Modiano, Manuel
    Cohen, Gary
    Pro, Barbara
    Romaguera, Jorge
    Stromatt, Scott
    BLOOD, 2006, 108 (11) : 781A - 781A
  • [36] A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma
    O'Donnell, RT
    Shen, S
    Denardo, SJ
    Wun, T
    Kukis, DL
    Goldstein, DS
    Denardo, GL
    ANTICANCER RESEARCH, 2000, 20 (5C) : 3647 - 3655
  • [37] IDEC-C2B8 anti-CD20 phase II trial: Results on bone marrow and peripheral blood tumor response in patients with low-grade non-Hodgkin's lymphoma (NHL)/lymphoproliferative disorders (LPD).
    Nguyen, D
    Amess, J
    Hendry, L
    Regeer, B
    BLOOD, 1997, 90 (10) : 2277 - 2277
  • [38] Cellular localization pattern of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in a patient with low-grade non-Hodgkin's lymphoma (NHL).
    Jacobs, SA
    Harrison, AM
    Swerdlow, SH
    Foon, KA
    Avril, N
    Vidnovic, N
    McCarty, KS
    Saville, W
    BLOOD, 2004, 104 (11) : 226B - 226B
  • [39] Dose finding trial of yttrium 90 (90Y) ibriturnomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
    Flinn, IW
    Kahl, BS
    Frey, E
    Bianco, JA
    Hammes, RJI
    Billing, LS
    Swinnen, LJ
    Sgouros, G
    Wahl, RL
    BLOOD, 2004, 104 (11) : 256A - 256A
  • [40] Ongoing results of a phase I trial of two sequential doses of Y-90 ibritumomab tiuxetan (Zevaline) for patients with relapsed low-grade non-Hodgkin lymphoma (NHL)
    Wiseman, G
    Geyer, S
    Porrata, L
    Inwards, D
    Colgan, J
    White, W
    Micallef, I
    Lacy, M
    Ansell, S
    Johnston, P
    Witzig, T
    ANNALS OF ONCOLOGY, 2005, 16 : 135 - 135
12345